EP2912179A4 - Oligonucléotides antisens c-myc et ses procédés d'utilisation pour le traitement de troubles de la prolifération cellulaire - Google Patents

Oligonucléotides antisens c-myc et ses procédés d'utilisation pour le traitement de troubles de la prolifération cellulaire

Info

Publication number
EP2912179A4
EP2912179A4 EP13849097.4A EP13849097A EP2912179A4 EP 2912179 A4 EP2912179 A4 EP 2912179A4 EP 13849097 A EP13849097 A EP 13849097A EP 2912179 A4 EP2912179 A4 EP 2912179A4
Authority
EP
European Patent Office
Prior art keywords
methods
same
antisense oligonucleotides
proliferative disorders
treat cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP13849097.4A
Other languages
German (de)
English (en)
Other versions
EP2912179A1 (fr
Inventor
Sergei M Gryaznov
Daria Zielinska
Ronald A Pruzan
Jeffrey N Lindquist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/829,594 external-priority patent/US9228189B2/en
Application filed by Geron Corp filed Critical Geron Corp
Publication of EP2912179A1 publication Critical patent/EP2912179A1/fr
Publication of EP2912179A4 publication Critical patent/EP2912179A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP13849097.4A 2012-10-26 2013-10-25 Oligonucléotides antisens c-myc et ses procédés d'utilisation pour le traitement de troubles de la prolifération cellulaire Pending EP2912179A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261719348P 2012-10-26 2012-10-26
US201361784910P 2013-03-14 2013-03-14
US13/829,594 US9228189B2 (en) 2012-10-26 2013-03-14 C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
PCT/US2013/066960 WO2014066851A1 (fr) 2012-10-26 2013-10-25 Oligonucléotides antisens c-myc et ses procédés d'utilisation pour le traitement de troubles de la prolifération cellulaire

Publications (2)

Publication Number Publication Date
EP2912179A1 EP2912179A1 (fr) 2015-09-02
EP2912179A4 true EP2912179A4 (fr) 2016-10-12

Family

ID=53002976

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13849097.4A Pending EP2912179A4 (fr) 2012-10-26 2013-10-25 Oligonucléotides antisens c-myc et ses procédés d'utilisation pour le traitement de troubles de la prolifération cellulaire

Country Status (4)

Country Link
EP (1) EP2912179A4 (fr)
CA (2) CA2887702C (fr)
HK (1) HK1214293A1 (fr)
WO (1) WO2014066851A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020124043A1 (fr) * 2018-12-13 2020-06-18 Gordon Erlinda M Procédés d'exploitation d'oncogènes pilotes le long de la voie biologique de la cycline g1 humaine pour thérapie génique du cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997036005A1 (fr) * 1996-03-26 1997-10-02 Lynx Therapeutics, Inc. Traitements a base d'oligonucleotides et compositions contre les melanomes humains
WO2001018015A1 (fr) * 1999-09-10 2001-03-15 Geron Corporation Thiophosphoramidates n3'→p5' oligonucleotidiques: synthese et utilisation
WO2001083740A2 (fr) * 2000-05-04 2001-11-08 Avi Biopharma, Inc. Composition anti-sens a region d'epissage et methode associee
US6867294B1 (en) * 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
WO2005023994A2 (fr) * 2003-09-09 2005-03-17 Geron Corporation Oligonucleotides modifies destines a l'inhibition de la telomerase
WO2011075656A1 (fr) * 2009-12-18 2011-06-23 The University Of British Columbia Procédés et compositions pour l'administration d'acides nucléiques

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
AU598946B2 (en) 1987-06-24 1990-07-05 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
EP0406309A4 (en) 1988-03-25 1992-08-19 The University Of Virginia Alumni Patents Foundation Oligonucleotide n-alkylphosphoramidates
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5721218A (en) 1989-10-23 1998-02-24 Gilead Sciences, Inc. Oligonucleotides with inverted polarity
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
EP0455905B1 (fr) 1990-05-11 1998-06-17 Microprobe Corporation Bâtonnets d'immersion pour l'essai d'hybridition des acides nucléiques et procédés pour l'immobilisation covalente d'oligonucléotides
BR9106702A (pt) 1990-07-27 1993-06-08 Isis Pharmaceuticals Inc Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
AU3222793A (en) 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
EP0577558A2 (fr) 1992-07-01 1994-01-05 Ciba-Geigy Ag Nucléosides carbocycliques contenant des noyaux bicycliques, oligonucléotides en dérivant, procédé pour leur préparation, leur application et des intermédiaires
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
CA2159631A1 (fr) 1993-03-30 1994-10-13 Sanofi Analogues de nucleoside acycliques et sequences d'oligonucleotides qui en renferment
DE4311944A1 (de) 1993-04-10 1994-10-13 Degussa Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
HUT76094A (en) * 1994-03-18 1997-06-30 Lynx Therapeutics Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
WO2008094640A2 (fr) * 2007-01-30 2008-08-07 Geron Corporation Composés à effets antiadhésifs sur les cellules cancéreuses

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997036005A1 (fr) * 1996-03-26 1997-10-02 Lynx Therapeutics, Inc. Traitements a base d'oligonucleotides et compositions contre les melanomes humains
US6867294B1 (en) * 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
WO2001018015A1 (fr) * 1999-09-10 2001-03-15 Geron Corporation Thiophosphoramidates n3'→p5' oligonucleotidiques: synthese et utilisation
WO2001083740A2 (fr) * 2000-05-04 2001-11-08 Avi Biopharma, Inc. Composition anti-sens a region d'epissage et methode associee
WO2005023994A2 (fr) * 2003-09-09 2005-03-17 Geron Corporation Oligonucleotides modifies destines a l'inhibition de la telomerase
WO2011075656A1 (fr) * 2009-12-18 2011-06-23 The University Of British Columbia Procédés et compositions pour l'administration d'acides nucléiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GRYAZNOV S ET AL: "OLIGONUCLEOTIDE N3'-P5' PHOSPHORAMIDATES AS ANTISENSE AGENTS", NUCLEIC ACIDS RESEARCH, vol. 24, no. 8, 15 April 1996 (1996-04-15), pages 1508 - 1514, XP000582450, ISSN: 0305-1048, DOI: 10.1093/NAR/24.8.1508 *
GRYAZNOV, S.: "Oligonucleotide N3'-->P5' phosphoramidates as potential therapeutic agents.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1489, no. 1, 10 December 1999 (1999-12-10), pages 131 - 140, XP055271472, ISSN: 0006-3002 *
T. SKORSKI ET AL: "Antileukemia effect of c-myc N3'->P5' phosphoramidate antisense oligonucleotides in vivo", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 94, no. 8, 15 April 1997 (1997-04-15), US, pages 3966 - 3971, XP055271471, ISSN: 0027-8424, DOI: 10.1073/pnas.94.8.3966 *

Also Published As

Publication number Publication date
EP2912179A1 (fr) 2015-09-02
CA2887702C (fr) 2023-08-01
HK1214293A1 (zh) 2016-07-22
CA3201145A1 (fr) 2014-05-01
WO2014066851A1 (fr) 2014-05-01
CA2887702A1 (fr) 2014-05-01

Similar Documents

Publication Publication Date Title
IL267066B (en) Activin-actrii antagonists and their use for the treatment of bone and other disorders
HRP20181976T1 (hr) Postupci za liječenje poremećaja gubitka kose
HRP20171254T1 (hr) Oligonukleotidi koji moduliraju rnk s poboljšanim karakteristikama za liječenje neuromišićnih poremećaja
RS56595B1 (sr) Derivati estrogena za upotrebu u lečenju neuroloških poremećaja
HRP20190038T1 (hr) Derivati pantotenata namijenjeni liječenju neuroloških poremećaja
IL235127A (en) Hpn-100 for use in the treatment of nitrogen-related diseases
GB201213782D0 (en) Process and dressing
EP2858634A4 (fr) Composés pour le traitement de l'inflammation et de la douleur
HK1214293A1 (zh) 反義寡核苷酸和利用其治療細胞增殖性疾病的方法
EP2861228A4 (fr) Composés destinés au traitement de l'inflammation et de la douleur
HK1243733A1 (zh) 用於治療神經肌肉障礙的具有改善特性的rna調節寡核苷酸
AU2012902430A0 (en) Antisense Molecules and Methods for Treating SMN-related Pathologies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150521

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/113 20100101AFI20160517BHEP

Ipc: A61P 35/00 20060101ALI20160517BHEP

Ipc: A61K 31/7125 20060101ALI20160517BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1214293

Country of ref document: HK

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160914

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/113 20100101AFI20160908BHEP

Ipc: A61K 31/7125 20060101ALI20160908BHEP

Ipc: A61P 35/00 20060101ALI20160908BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20171124

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GERON CORPORATION

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GERON CORPORATION